BioCryst Pharmaceuticals, Inc.

Good morning and welcome to the BioCHRIST fourth quarter 2022 earnings conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. please note this event is being recorded. I would now like to turn the conference over to John Bluest at Biochrist. Please go ahead.

Thanks, Andrea. Good morning and welcome to Biochrist's fourth quarter and year-end 2022 Corporate Update and Financial Results Conference Call. Today's press release and accompanying slides are available on our website. Participating with me today are CEO John Stonehouse, CFO Anthony Doyle, Chief Commercial Officer Charlie Geyer, and Chief R&D Officer Dr. Helen Thackeray. Following our remarks, we'll answer your questions. Before we begin, please note that today's conference call will contain forward-looking statements, including those statements regarding future results on audited and forward-looking financial information, as well as the company's future performance and or achievements. These statements are subject to known and unknown risks and uncertainties, which may cause our actual results, performance, or achievements to be materially different from any future results or performance expressed or implied in this presentation. You should not place undue reliance on these forward-looking statements. For additional information, including a detailed discussion of our risk factors, please refer to the company's documents filed with the Securities and Exchange Commission, which can be accessed on our website. I'd now like to turn the call over to John Stonehouse.

Thanks, John. 2022 was another outstanding year for Ladeo as we doubled sales in our second full year of launch on top of the fantastic start we had in the first year. It shouldn't be surprising given the excellent safety, efficacy, and one's daily oral profile. we are consistently hearing from patients that Orladeo is changing their lives. As you will hear from Charlie, in the U.S., our prescriber base continues to grow both in breadth and depth. In addition, Orladeo is already commercially available to HAE patients in 15 countries around the world. The ability of Orladeo to deliver meaningful results for patients is driving the steady patient growth we are seeing quarter after quarter, and in 2023, we expect this strong, steady demand to continue, leading to the global sales of no less than $320 million. Our goal with this guidance is very simple, to be accurate. Accurate guidance has been our track record since launch because we're the only ones with access to the prescription data through our sole source specialty pharmacy. With our sales performance in 2021 and 2022 and our guidance in 2023, You now have three data points to get a sense of the slope of the Orladeo launch. We are on a trajectory to achieve peak global sales of $1 billion, and our IP for Orladeo extends out to 2039, so we expect to be at peak sales for many, many years. While our revenues continue to grow, we expect our operating expenses to be flat year over year, as we have made and will continue to make thoughtful capital allocation decisions on our pipeline investments. This reduction in net cash use has strengthened our financial position, moved us closer to profitability. You will hear more detail on this from Anthony shortly. And I'll turn the call over to Charlie to review Orladeo performance in more detail.